NO20021780D0 - Bicykliske aminosyrer som farmasöytiske midler - Google Patents

Bicykliske aminosyrer som farmasöytiske midler

Info

Publication number
NO20021780D0
NO20021780D0 NO20021780A NO20021780A NO20021780D0 NO 20021780 D0 NO20021780 D0 NO 20021780D0 NO 20021780 A NO20021780 A NO 20021780A NO 20021780 A NO20021780 A NO 20021780A NO 20021780 D0 NO20021780 D0 NO 20021780D0
Authority
NO
Norway
Prior art keywords
amino acids
pharmaceutical agents
bicyclic amino
bicyclic
pharmaceutical
Prior art date
Application number
NO20021780A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021780L (no
Inventor
Justin Stephen Bryans
David Clive Blakemore
Simon Osborne
Jean-Marie Receveur
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20021780L publication Critical patent/NO20021780L/no
Publication of NO20021780D0 publication Critical patent/NO20021780D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/22—All rings being cycloaliphatic the ring system containing eight carbon atoms, e.g. pentalene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/24—All rings being cycloaliphatic the ring system containing nine carbon atoms, e.g. perhydroindane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
NO20021780A 1999-10-20 2002-04-16 Bicykliske aminosyrer som farmasöytiske midler NO20021780D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16072599P 1999-10-20 1999-10-20
PCT/US2000/028687 WO2001028978A1 (en) 1999-10-20 2000-10-17 Bicyclic amino acids as pharmaceutical agents

Publications (2)

Publication Number Publication Date
NO20021780L NO20021780L (no) 2002-04-16
NO20021780D0 true NO20021780D0 (no) 2002-04-16

Family

ID=22578159

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20021780A NO20021780D0 (no) 1999-10-20 2002-04-16 Bicykliske aminosyrer som farmasöytiske midler
NO20043663A NO20043663L (no) 1999-10-20 2004-09-01 Bicykliske aminosyrer som farmasoytiske midler

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20043663A NO20043663L (no) 1999-10-20 2004-09-01 Bicykliske aminosyrer som farmasoytiske midler

Country Status (50)

Country Link
US (2) US6689906B1 (cs)
EP (2) EP1226110B1 (cs)
JP (2) JP3632191B2 (cs)
KR (2) KR100593349B1 (cs)
CN (1) CN1165518C (cs)
AP (2) AP2004003186A0 (cs)
AR (2) AR026087A1 (cs)
AT (2) ATE358116T1 (cs)
AU (2) AU778871B2 (cs)
BG (2) BG108860A (cs)
BR (1) BR0014972B1 (cs)
CA (1) CA2386297C (cs)
CO (1) CO5280060A1 (cs)
CR (1) CR6620A (cs)
CU (1) CU23112A3 (cs)
CZ (1) CZ295960B6 (cs)
DE (2) DE60034157T2 (cs)
DO (1) DOP2000000083A (cs)
DZ (1) DZ3197A1 (cs)
EA (1) EA005206B1 (cs)
EC (1) ECSP045393A (cs)
EE (1) EE200200211A (cs)
ES (2) ES2282785T3 (cs)
GE (1) GEP20043297B (cs)
GT (2) GT200000183A (cs)
HK (1) HK1049826B (cs)
HN (1) HN2000000224A (cs)
HR (2) HRP20040709A2 (cs)
HU (1) HUP0203325A3 (cs)
IL (3) IL149143A0 (cs)
IS (2) IS6348A (cs)
MA (1) MA26842A1 (cs)
MX (1) MXPA02003229A (cs)
MY (1) MY127678A (cs)
NO (2) NO20021780D0 (cs)
NZ (1) NZ517961A (cs)
OA (1) OA12070A (cs)
PA (1) PA8505201A1 (cs)
PE (1) PE20010740A1 (cs)
PL (1) PL354607A1 (cs)
PT (1) PT1226110E (cs)
SI (1) SI1226110T1 (cs)
SK (1) SK5232002A3 (cs)
SV (1) SV2001000188A (cs)
TR (2) TR200201094T2 (cs)
TW (2) TW200505824A (cs)
UA (1) UA72931C2 (cs)
WO (1) WO2001028978A1 (cs)
YU (2) YU73004A (cs)
ZA (1) ZA200202543B (cs)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7164034B2 (en) 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
DK1296671T3 (da) * 2000-06-26 2008-06-16 Warner Lambert Co Gabapentinanaloger til sövnforstyrrelser
US6620829B2 (en) 2000-10-17 2003-09-16 Warner-Lambert Company Method of treating noninflammatory cartilage damage
EP1226820A1 (en) * 2001-01-26 2002-07-31 Warner-Lambert Company Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders
SK12822003A3 (sk) * 2001-04-19 2004-04-06 Warner - Lambert Company Llc Fúzne bicyklické alebo tricyklické aminokyseliny
GB2375109A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Process for preparing bicyclic amino acid
GB2375108A (en) * 2001-05-04 2002-11-06 Warner Lambert Co Production of a bicycloheptanone
DK1404324T4 (da) * 2001-06-11 2011-07-11 Xenoport Inc Prolægemidler af GABA analoger, sammensætninger og anvendelser deraf
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
PL371944A1 (en) 2002-01-31 2005-07-11 Warner-Lambert Company Llc Alpha 2 delta ligands to treat tinnitus
EP1480639A1 (en) * 2002-02-22 2004-12-01 Warner-Lambert Company LLC Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
AU2003239752A1 (en) * 2002-06-27 2004-01-19 Warner-Lambert Company Llc Use of an alpha2delta ligand such as gabapentin or pregabalin for treating ttention deficit hyperactivity disorder
GB0219024D0 (en) * 2002-08-15 2002-09-25 Pfizer Ltd Synergistic combinations
WO2004016260A1 (en) * 2002-08-15 2004-02-26 Pfizer Limited Therapeutic use of fused bicyclic or tricyclic amino acids
US7419981B2 (en) 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US7018818B2 (en) 2002-10-04 2006-03-28 Pfizer Inc. Intermediates in the preparation of therapeutic fused bicyclic amino acids
GB0223072D0 (en) 2002-10-04 2002-11-13 Pfizer Ltd Cyclic nitromethyl acetic acid derivatives
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
NZ539972A (en) 2002-12-13 2008-05-30 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
EP1572188A1 (en) 2002-12-13 2005-09-14 Warner-Lambert Company LLC Pregabalin derivatives for the treatment of fibromyalgia and other disorders
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
CN1849153A (zh) 2003-09-12 2006-10-18 辉瑞大药厂 含有α－2－δ配体和5－羟色胺/去甲肾上腺素重摄取抑制剂的组合物
WO2006092692A1 (en) * 2005-03-01 2006-09-08 Pfizer Limited Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain
AR061728A1 (es) * 2006-06-30 2008-09-17 Pfizer Prod Inc Composicion para tratamiento usando compuestos selectivos alfa-2-delta-1
PT2125021E (pt) 2006-12-22 2011-07-26 Recordati Ireland Ltd Terapia de combinação de distúrbios do tracto urinário inferior com 2 ligandos e nsaid
PT2192109E (pt) 2007-09-28 2013-12-09 Daiichi Sankyo Co Ltd Derivado de -aminoácido bicíclico
BRPI1013482B8 (pt) 2009-03-26 2021-05-25 Daiichi Sankyo Co Ltd método para produzir um composto
WO2012169475A1 (ja) 2011-06-08 2012-12-13 第一三共株式会社 クライゼン転位反応による二環性化合物の製造方法
CA2838650C (en) 2011-06-08 2016-07-12 Daiichi Sankyo Company, Limited Method for producing bicyclic compound via iminium salt
IN2014MN01046A (cs) 2011-12-15 2015-05-01 Daiichi Sankyo Companyltd
BR112014025158B1 (pt) 2012-04-10 2021-09-21 Daiichi Sankyo Company, Limited Método para produzir um composto
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018166855A1 (en) 2017-03-16 2018-09-20 Basf Se Heterobicyclic substituted dihydroisoxazoles
CN113045410A (zh) * 2021-03-29 2021-06-29 华东理工大学 一种双环降二萜类化合物及其合成基因及制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641129A (en) * 1969-06-17 1972-02-08 Merck & Co Inc Antifibrinolytic compounds
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1999021824A1 (en) 1997-10-27 1999-05-06 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents

Also Published As

Publication number Publication date
AU2005201268A1 (en) 2005-04-21
KR100593349B1 (ko) 2006-06-26
AU778871B2 (en) 2004-12-23
KR20020040900A (ko) 2002-05-30
CN1382118A (zh) 2002-11-27
US20040152779A1 (en) 2004-08-05
CZ295960B6 (cs) 2005-12-14
EA005206B1 (ru) 2004-12-30
TR200500221T2 (tr) 2005-03-21
US6689906B1 (en) 2004-02-10
DZ3197A1 (fr) 2001-04-26
YU73004A (sh) 2005-11-28
WO2001028978A1 (en) 2001-04-26
CU23112A3 (es) 2006-02-27
DE60034157T2 (de) 2007-12-13
ES2282785T3 (es) 2007-10-16
NZ517961A (en) 2002-12-20
US6835751B2 (en) 2004-12-28
IL149143A (en) 2007-02-11
HK1049826B (zh) 2005-02-25
BR0014972A (pt) 2002-07-16
JP2003512348A (ja) 2003-04-02
MA26842A1 (fr) 2004-12-20
HUP0203325A2 (hu) 2003-02-28
JP3632191B2 (ja) 2005-03-23
DOP2000000083A (es) 2002-03-30
IS6348A (is) 2002-04-17
TWI225855B (en) 2005-01-01
HRP20040709A2 (en) 2004-12-31
AP2002002517A0 (en) 2002-06-30
PL354607A1 (en) 2004-01-26
CR6620A (es) 2004-02-02
IS7497A (is) 2004-10-08
EE200200211A (et) 2003-06-16
TR200201094T2 (tr) 2002-09-23
NO20021780L (no) 2002-04-16
PA8505201A1 (es) 2002-08-29
ATE293590T1 (de) 2005-05-15
PE20010740A1 (es) 2001-07-27
OA12070A (en) 2003-11-10
GT200000183AA (es) 2005-06-17
HUP0203325A3 (en) 2003-12-29
SV2001000188A (es) 2001-09-07
ES2237464T3 (es) 2005-08-01
KR20060013701A (ko) 2006-02-13
BG108860A (en) 2006-03-31
MY127678A (en) 2006-12-29
HRP20020428B1 (en) 2006-02-28
PT1226110E (pt) 2005-07-29
BR0014972B1 (pt) 2011-09-06
AP2004003186A0 (en) 2004-12-31
UA72931C2 (uk) 2005-05-16
CO5280060A1 (es) 2003-05-30
HN2000000224A (es) 2001-04-11
DE60019628T2 (de) 2006-01-19
EA200200293A1 (ru) 2002-10-31
DE60019628D1 (de) 2005-05-25
HRP20020428A2 (en) 2005-02-28
ATE358116T1 (de) 2007-04-15
CA2386297A1 (en) 2001-04-26
AR026087A1 (es) 2002-12-26
JP3744928B2 (ja) 2006-02-15
DE60034157D1 (de) 2007-05-10
ECSP045393A (es) 2004-10-23
KR100566462B1 (ko) 2006-03-31
MXPA02003229A (es) 2002-09-30
EP1226110A1 (en) 2002-07-31
AR045456A2 (es) 2005-10-26
CZ20021310A3 (cs) 2003-05-14
NO20043663L (no) 2002-04-16
IL164060A0 (en) 2005-12-18
ZA200202543B (en) 2003-09-23
AU1092001A (en) 2001-04-30
HK1049826A1 (en) 2003-05-30
TW200505824A (en) 2005-02-16
EP1506955A1 (en) 2005-02-16
EP1506955B1 (en) 2007-03-28
GEP20043297B (en) 2004-01-12
GT200000183A (es) 2000-10-19
YU29302A (sh) 2005-06-10
SK5232002A3 (en) 2003-07-01
CN1165518C (zh) 2004-09-08
BG106719A (bg) 2003-02-28
CA2386297C (en) 2010-02-09
SI1226110T1 (en) 2005-08-31
IL149143A0 (en) 2002-11-10
EP1226110B1 (en) 2005-04-20
JP2005036009A (ja) 2005-02-10

Similar Documents

Publication Publication Date Title
NO20021780L (no) Bicykliske aminosyrer som farmasöytiske midler
DK1212327T3 (da) Pyrazolopyrimidiner som terapeutiske midler
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
NO20015175L (no) Farmasöytisk sammensetning
NO20002217L (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
ID24654A (id) Formulasi farmasi omeprazola
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
NO20022887L (no) Lipopeptider som antibakterielle midler
DK1163239T3 (da) Modificerede aminosyreamider som CGRP-antagonister
NO20016006D0 (no) Valensplattformmolekyler som innbefatter aminooksygrupper
NO993901L (no) Bisykliske aminosyrer
DK1218383T3 (da) Biocykliske imidazo-5-yl-aminoderivater
NO20022606D0 (no) Farmasöytiske kombinasjoner
DK1227817T3 (da) Ciclesonid-holdigt vandigt farmaceutisk præparat
ID30032A (id) Formulasi farmasi
FI4488U1 (fi) Farmaseuttinen koostumus
AR025867A1 (es) Formulacion portasdora farmaceutica
EE200100697A (et) Farmatseutiline kompleks
NO20002321D0 (no) Bifenylderivater som farmasøytiske midler
NO20004816D0 (no) Ny farmasøytisk formulering
DK1226110T3 (da) Bicycliske aminosyrer som farmaceutiske midler
SE9803952D0 (sv) Pharmaceutical formulation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application